ABT-518 - CAS 286845-00-9
Catalog number: 286845-00-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C21H22F3NO8S
Molecular Weight:
505.461
COA:
Inquire
Description:
ABT-518 is an inhibitor of matrix metalloproteinases, which are associated with tumor growth and development of metastasis.
MSDS:
Inquire
InChIKey:
IVPPTWCRAFCOFJ-RTBURBONSA-N
InChI:
InChI=1S/C21H22F3NO8S/c1-20(2)30-11-19(33-20)18(25(27)13-26)12-34(28,29)17-9-7-15(8-10-17)31-14-3-5-16(6-4-14)32-21(22,23)24/h3-10,13,18-19,27H,11-12H2,1-2H3/t18-,19-/m1/s1
Canonical SMILES:
CC1(OCC(O1)C(CS(=O)(=O)C2=CC=C(C=C2)OC3=CC=C(C=C3)OC(F)(F)F)N(C=O)O)C
Current Developer:
Abbott Laboratories.
1.Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.
Crul M1, Beerepoot LV, Stokvis E, Vermaat JS, Rosing H, Beijnen JH, Voest EE, Schellens JH. Cancer Chemother Pharmacol. 2002 Dec;50(6):473-8. Epub 2002 Oct 25.
PURPOSE: To investigate the pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase (MMP) inhibitor ABT-518.
2.Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Stokvis E1, Rosing H, Crul M, Rieser MJ, Heck AJ, Schellens JH, Beijnen JH. J Mass Spectrom. 2004 Mar;39(3):277-88.
A liquid chromatographic/tandem mass spectrometric (LC/MS/MS) assay for the quantitative analysis of the novel anticancer drug ABT-518 and the screening of six potential metabolites in human plasma has been developed and validated to support a phase I study with the drug. ABT-518 is an inhibitor of matrix metalloproteinases, which are associated with tumor growth and development of metastasis. Plasma samples were prepared for analysis using a simple solid-phase extraction method on phenyl cartridges. LC separation was performed on a Zorbax extend C18 column (150 x 2.1 mm i.d., 5 microm particle size) using a mobile phase of methanol-aqueous 10 mM ammonium hydroxide (80:20, v/v) pumped at a flow-rate of 0.2 ml min(-1). An API2000 triple-quadrupole mass spectrometer was used for specific and sensitive detection. The best chromatographic speed (total run time 8 min) and peak shapes were obtained by employing an alkaline mobile phase (pH in aqueous phase approximately 10).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 190508-50-0 AT 1015

AT 1015
(CAS: 190508-50-0)

AT 1015 has been found to be a 5-HT2A receptor antagonist and exhibit antithrombotic activities.

Terutroban
(CAS: 165538-40-9)

Terutroban is a potent, orally active antagonist of the thromboxane/prostaglandin A2(TP) receptor (IC50 = 16.4 nM). In guinea pigs it also inhibits U 46619 indu...

CAS 69-72-7 Salicylic acid

Salicylic acid
(CAS: 69-72-7)

Salicylic acid is a natural product extract from Willow bark, well known as an antiinflammatory inhibitor of cyclooxygenase activity. It is widely used in organ...

CAS 1312445-63-8 NVP-BKM120 Hydrochloride

NVP-BKM120 Hydrochloride
(CAS: 1312445-63-8)

NVP-BKM120 Hcl(BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM, respectively.

CAS 903576-44-3 BF 2649

BF 2649
(CAS: 903576-44-3)

Pitolisant hydrochloride is an antagonist of the histamine H3 receptor, which is used for the treatment of narcolepsy with or without cataplexy in adult patient...

CAS 70724-25-3 Carbazeran

Carbazeran
(CAS: 70724-25-3)

Carbazeran is an AO (Aldehyde oxidase) substrate. It is a phosphodiesterase PDE-II and PDE-III inhibitor that can produce concentration-dependent positive inotr...

CAS 1433953-83-3 SAR131675

SAR131675
(CAS: 1433953-83-3)

SAR131675 dose dependently inhibits the proliferation of primary human lymphatic cells, induced by the VEGFR-3 ligands VEGFC and VEGFD, with an IC50 of about 20...

CAS 217799-03-6 KP496

KP496
(CAS: 217799-03-6)

KP496, a novel dual antagonist of cysLT receptor and TP, is currently in clinical development as a dry powder inhaler. KP496 inhibited epithelial hypertrophy an...

Chemical Structure

CAS 286845-00-9 ABT-518

Quick Inquiry

Verification code

Featured Items